influenza
infect
repres
consider
global
burden
affect
adult
popul
annual
influenza
epidem
year
million
case
sever
ill
death
thought
result
epidem
worldwid
southeast
asia
consid
global
influenza
epicentr
sever
pandem
epidem
strain
known
origin
china
hong
kong
sinc
furthermor
china
gener
acknowledg
area
high
influenza
attack
rate
due
high
popul
densiti
yearround
circul
viru
tropic
region
china
pneumonia
influenza
combin
rank
fourth
lead
caus
death
adult
year
age
due
weaken
immun
respons
elderli
increas
risk
influenza
relat
complic
china
annual
mortal
rate
pneumonia
influenza
report
rise
person
elderli
year
age
repres
increas
agestandardis
annual
mortal
rate
person
furthermor
report
number
influenzaassoci
death
hong
kong
cardiorespiratori
diseas
pneumonia
influenza
chronic
obstruct
pulmonari
diseas
ischaem
heart
diseas
higher
elderli
death
compar
adult
death
year
age
peak
influenza
circul
shown
coincid
increas
mortal
condit
elderli
account
approxim
associ
death
addit
increas
number
death
hospitalis
rate
pneumonia
influenza
also
high
elderli
influenza
vaccin
effect
studi
extens
mainli
temper
region
convent
influenza
vaccin
confer
protect
laboratoryconfirm
influenza
young
adult
year
age
howev
vaccin
less
effect
elderli
due
part
elderli
wane
immun
evalu
vaccin
respons
howev
import
also
consid
racial
background
exampl
among
racial
divers
healthi
elderli
popul
usa
reduc
respons
influenza
vaccin
observ
among
elderli
african
american
compar
elderli
caucasian
latino
furthermor
racial
differ
relat
vaccin
observ
taiwan
among
han
chines
children
compar
aborigin
children
higher
titr
hepat
b
vaccin
report
han
chines
children
hong
kong
taiwan
china
vaccin
shown
offer
protect
influenza
influenza
vaccin
prevent
approxim
influenzarel
hospitalis
admiss
hong
kong
winter
season
strongli
associ
reduct
pneumonia
heart
diseas
stroke
diabet
mellitu
renal
diseas
taiwan
vaccin
effect
howev
also
report
lower
elderli
chines
peopl
adult
chines
peopl
versu
respect
despit
avail
effect
vaccin
coverag
rate
low
china
exampl
gener
vaccin
rate
among
urban
popul
beij
fall
year
age
thu
current
avail
vaccin
offer
optim
protect
elderli
vaccin
coverag
rate
low
elderli
chines
peopl
increas
risk
influenza
relat
complic
china
world
largest
popul
elderli
peopl
million
influenza
repres
consider
health
econom
burden
meet
global
challeng
present
wane
immun
elderli
vaccin
offer
elderli
enhanc
immunogen
increas
clinic
protect
requir
addit
adjuv
subunit
influenza
vaccin
subunit
influenza
vaccin
novarti
vaccin
shown
enhanc
immun
respons
offer
increas
clinic
protect
elderli
subject
compar
nonadjuv
subunit
influenza
vaccin
furthermor
enhanc
immunogen
observ
elderli
subject
underli
chronic
condit
especi
high
risk
influenza
complic
vaccin
elderli
subject
subunit
influenza
vaccin
also
confer
protect
broader
rang
influenza
viru
strain
nonadjuv
subunit
influenza
vaccin
associ
reduc
risk
hospitalis
pneumonia
cerebrovascular
diseas
noninstitutionalis
elderli
subject
china
registr
use
elderli
peopl
current
consider
reason
randomis
compar
trial
perform
larg
cohort
elderli
chines
peopl
assess
safeti
immunogen
nonadjuv
subunit
influenza
vaccin
vaccin
well
toler
elderli
subject
clinic
trial
vaccinerel
seriou
advers
event
sae
report
phase
trial
prerequisit
continu
phase
iiiii
trial
phase
iiiii
trial
overal
incid
system
reaction
ae
gener
similar
subunit
group
howev
incid
local
reaction
significantli
p
higher
group
compar
subunit
group
versu
respect
tabl
indur
inject
site
significantli
p
frequent
subunit
group
compar
group
versu
respect
tabl
pain
inject
site
fever
axillari
temperatur
significantli
p
frequent
group
compar
subunit
group
versu
versu
respect
tabl
local
system
reaction
gener
mild
moder
transient
particular
fever
mainli
class
mild
moder
subunit
group
pain
classifi
mild
vaccinerel
sae
report
larg
studi
subunit
group
howev
vaccinerel
sae
high
fever
report
one
subject
group
tabl
prevaccin
gmt
similar
vaccin
group
three
influenza
strain
test
baselin
seroprotect
rate
also
similar
vaccin
group
subject
vaccin
cohort
seroprotect
subunit
subunit
b
subunit
prior
vaccin
tabl
week
postvaccin
significantli
p
higher
gmt
report
vaccin
group
versu
baselin
data
shown
howev
group
postvaccin
gmt
three
strain
significantli
higher
compar
subunit
group
versu
respect
p
versu
respect
p
b
versu
respect
p
furthermor
gmt
ratio
day
day
b
strain
significantli
p
p
p
respect
greater
group
compar
subunit
group
figur
follow
analysi
data
includ
subject
seroprotect
titr
prior
vaccin
trend
found
higher
postvaccin
gmt
report
group
compar
subunit
group
b
strain
p
p
respect
figur
postvaccin
percentag
subject
seroprotect
strain
significantli
p
greater
vaccin
compar
subunit
vaccin
tabl
although
seroprotect
rate
subject
b
strain
higher
group
signific
differ
found
vaccin
group
addit
significantli
p
greater
number
previous
unprotect
elderli
subject
vaccin
group
demonstr
seroconvers
strain
compar
subunit
group
versu
respect
tabl
studi
demonstr
subunit
influenza
vaccin
well
toler
nonadjuv
subunit
influenza
vaccin
elderli
chines
subject
although
number
incid
solicit
local
reaction
vaccin
group
greater
subunit
group
gener
mild
moder
short
durat
subject
withdrew
studi
due
safeti
concern
furthermor
incid
injectionsit
pain
report
lower
report
studi
although
incid
fever
higher
report
previous
influenza
vaccin
increas
incid
evid
vaccin
use
studi
rather
vaccin
increas
appear
due
race
previou
studi
elderli
chines
subject
incid
fever
follow
vaccin
nonadjuv
influenza
vaccin
find
agreement
publish
result
clinic
trial
conduct
elderli
caucasian
popul
europ
trial
support
registr
vaccin
europ
conclud
addit
subunit
influenza
vaccin
caus
clinic
import
chang
safeti
profil
influenza
vaccin
date
million
dose
subunit
influenza
vaccin
sold
demonstr
good
safeti
profil
evalu
postmarket
pharmacovigil
case
report
n
septemb
april
confirm
vaccin
subunit
influenza
vaccin
associ
low
frequenc
advers
reaction
evalu
primari
pre
postvaccin
gmt
gmt
ratio
secondari
proport
subject
protect
antibodi
titr
demonstr
seroconvers
postvaccin
immunogen
paramet
show
subunit
vaccin
abl
induc
immun
respons
elderli
chines
subject
significantli
p
higher
antibodi
titr
induc
vaccin
compar
subunit
vaccin
furthermor
safeti
profil
immunogen
result
agre
result
trial
conduct
europ
three
influenza
strain
test
nonadjuv
vaccin
met
least
one
criterion
european
committe
medicin
product
human
use
chmp
criteria
immunogen
evalu
season
influenza
vaccin
requir
vaccin
licensur
vaccin
trend
higher
immunogen
influenza
strain
compar
b
strain
note
high
prevaccin
titr
record
studi
especi
could
explain
part
vaccin
strain
anew
includ
vaccin
formul
sever
influenza
season
previou
season
furthermor
epidemiolog
standpoint
influenza
strain
often
domin
relev
strain
among
adult
elderli
predomin
circul
strain
guangxi
region
china
time
trial
conduct
well
document
level
hi
antibodi
titr
correl
seroprotect
influenza
thu
expect
increas
immunogen
lead
increas
clinic
protect
influenza
approach
wide
use
across
clinic
trial
programm
vaccin
field
studi
europ
vaccin
shown
offer
greater
clinic
protect
influenzalik
ill
compar
nonadjuv
vaccin
therefor
anticip
vaccin
may
also
offer
greater
clinic
protect
elderli
chines
subject
result
trial
use
subunit
influenza
vaccin
suggest
adjuv
vaccin
induc
greater
immun
respons
elderli
year
age
chines
subject
demonstr
good
toler
profil
compar
nonadjuv
subunit
influenza
vaccin
conclus
studi
result
strengthen
support
use
subunit
influenza
vaccin
among
elderli
popul
china
preliminari
phase
openlabel
studi
conduct
februarymarch
assess
safeti
subunit
influenza
vaccin
novarti
vaccin
elderli
chines
subject
studi
recruit
chines
subject
year
age
subject
administ
followup
sequenc
follow
safeti
trial
phase
iiiii
randomis
observerblind
control
studi
conduct
assess
safeti
immunogen
larg
cohort
elderli
year
age
chines
subject
subject
randomis
receiv
either
n
nonadjuv
subunit
influenza
vaccin
subunit
novarti
vaccin
n
vaccin
includ
strain
recommend
northern
hemispher
influenza
season
randomis
achiev
use
pem
statist
softwar
statist
teach
research
divis
west
china
univers
medic
scienc
releas
januari
ml
dose
administ
intramuscularli
deltoid
region
nondomin
arm
subject
invit
particip
trial
year
age
healthi
willing
provid
written
inform
consent
prior
studi
entri
subject
underli
diseas
chronic
tumour
autoimmun
diseas
progress
artherosclerosi
complic
diabet
mellitu
chronic
obstruct
pulmonari
disord
requir
oxygen
therapi
acut
progress
liver
renal
diseas
congest
heart
failur
subject
known
allergi
vaccin
compon
subject
laboratoryconfirm
influenza
vaccin
influenza
within
month
prior
enrol
subject
receiv
vaccin
investig
agent
within
week
prior
enrol
subject
current
infecti
diseas
includ
take
system
antibiot
antivir
pivot
safeti
studi
subsequ
trial
perform
accord
ethic
guidelin
declar
helsinki
good
clinic
practic
local
law
trial
start
studi
protocol
inform
consent
form
approv
local
ethic
committe
subject
sign
inform
consent
form
local
system
reaction
includ
advers
event
ae
monitor
record
day
postvaccin
phase
trial
day
postvaccin
phase
iiiii
trial
control
studi
phase
iiiii
trial
blood
sampl
taken
subject
prevaccin
day
postvaccin
day
haemagglutinin
inhibit
hi
antibodi
titr
measur
sampl
primari
paramet
geometr
mean
titr
gmt
anew
influenza
strain
measur
vaccin
pre
postvaccin
day
day
geometr
mean
titr
ratio
gmr
postvaccin
titr
versu
prevaccin
titr
also
report
secondari
paramet
influenza
strain
number
subject
seroprotect
hi
antibodi
titr
also
evalu
prevaccin
postvaccin
day
day
number
subject
achiev
seroconvers
defin
increas
hi
titr
nonneg
prevaccin
titr
rise
postvaccin
hi
titr
postvaccin
day
calcul
data
analys
use
sa
softwar
statist
signific
vaccin
group
data
describ
popul
baselin
characterist
calcul
use
student
ttest
chisquar
test
fisher
exact
test
necessari
analysi
covari
perform
calcul
confid
interv
gmt
day
gmt
day
covari
pair
ttest
perform
assess
differ
pre
postvaccin
gmt
within
vaccin
group
pvalu
consid
indic
statist
signific
studi
fund
novarti
vaccin
michel
pellegrini
audino
podda
employe
novarti
vaccin
remain
author
declar
compet
interest
rl
hf
respons
design
coordin
conduct
clinic
trial
statist
analysi
rl
hf
yl
yl
mp
ap
consult
clinic
result
prepar
manuscript
author
read
approv
final
manuscript
